Pioglitazone (PIO) is a thiazolidindione antidiabetic agent which improves insulin sensitivity and reduces blood glucose in experimental animals and treated patients. At the cellular level the actions of PIO in diabetic heart are poorly understood.
Introduction
Diabetes mellitus (DM) is a debilitating disease that is estimated to affect 366 million people by 2030 worldwide. The risk of coronary heart disease is increased in patients with T2DM and cardiovascular disease causes 80 % of all diabetic mortality and in 75 % of cases, it is as a result of coronary atherosclerosis (Schwartz 2010) . PIO belongs to the thiazolidinedione group of oral antidiabetic agents and is an agonist of peroxisome proliferator-activated receptor gamma (PPARγ) (Yki-Jarvinen 2004) . PIO decreases fasting and postprandial insulin concentrations and lowers blood pressure in spontaneously hypertensive rats (Grinsell et al. 2000) . In the spontaneously obese, insulin-resistant rhesus monkey PIO improved fasting and postprandial levels of insulin sensitivity, plasma glucose and lipid levels and also decreased systolic and mean arterial pressure (Kemnitz et al. 1994) . In a study to compare the risk of cardiovascular adverse effects in patients with T2DM treated with rosiglitazone, another thiazolidinedione, or PIO it was found that compared with pioglitazone, rosiglitazone is associated with an increased risk of myocardial infarction, heart failure, Vol. 67 and all-cause mortality in diabetic patients Wolski 2007, Chen et al. 2012) . High oral doses of PIO (500-1,000 mg/kg) administered to mice produce hypertrophy of the heart and mild congestion of the liver and kidneys (Chinnam et al. 2012) . PIO attenuates congestive heart failure-induced atrial structural remodeling and atrial fibrillation in rabbit heart (Shimano et al. 2008) . PIO has been shown to reduce angiotensin II-induced cardiac hypertrophy and ameliorate ventricular hypertrophy and fibrosis in hypertensive rat heart (Ye et al. 2005 , Li et al. 2010 , Kato et al. 2008 . In vivo biotelemetry studies have reported that daily oral PIO administration at concentrations ranging from 2.5 to 20 mg/kg over a period of 14 weeks had no significant effects on heart rate, PQ and QT intervals and QRS complex in GK rat hearts compared to controls (Salem et al. 2015) . In primary cultured rat cardiac myocytes myocardial hypertrophy induced by glucose and insulin was inhibited by PIO (Liu et al. 2007) . In canine ventricular myocytes action potential duration was shortened by PIO at concentrations ≥10 µM and this was accompanied by inhibition of several transmembrane ion currents including L-type Ca 2+ current, the rapid and slow component of delayed rectifier K + current and the transient outward K + current (Kistamas et al. 2013) . Little is known about the effect of PIO in diabetic heart. Therefore, the acute effects of PIO on ventricular myocyte shortening and Ca 2+ transport have been investigated in GK type 2 diabetic rat.
Methods

Experimental protocol
Approval for this project was obtained from the Animal Ethics Committee, College of Medicine & Health Sciences, United Arab Emirates University.
Twelve male GK (Taconic, Germantown, NY, USA) and twelve male Wistar control rats aged 8-10 months were used in these experiments. Animals were supplied with standard rat chow and water ad libitum. Body weight, heart weight and non-fasting blood glucose were measured immediately prior to experiments.
Ventricular myocyte isolation
Left ventricular myocytes were isolated according to previously described techniques (Salem et al. 2013) . In brief, animals were euthanized using a guillotine and hearts removed rapidly and mounted for retrograde perfusion according to the Langendorff method. Hearts were perfused at a constant flow rate of 8 ml.g heart -1 . , 0.60 mg/ml type 1 collagenase (Worthington Biochemical Corp, Lakewood, NJ, USA) and 0.075 mg/ml type XIV protease (Sigma, Taufkirchen, Germany). Left ventricle tissue was excised from the heart, minced and gently shaken in collagenasecontaining isolation solution supplemented with 1 % BSA. Cells were filtered from this solution at 4 min intervals and re-suspended in cell isolation solution containing 0.75 mM Ca 2+ and stored at 4 °C.
Measurement of ventricular myocyte shortening
Ventricular myocyte shortening was measured according to previously described techniques (Salem et al. 2013) . In brief, cells were allowed to settle on the glass bottom of a Perspex chamber mounted on the stage of an inverted microscope (Axiovert 35, Zeiss, Göttingen, Germany). Cells were superfused (3-5 ml/min) with normal Tyrode (NT) containing the following in mM: 140.0 NaCl, 5.0 KCl, 1.0 MgCl 2 , 10.0 glucose, 5.0 HEPES, 1.8 CaCl 2 (pH 7.4). Ventricular myocyte shortening was recorded before and after 10 min PIO treatment using a video edge detection system (VED-114, Crystal Biotech, Northborough, MA, USA). Superfusion of myocytes with NT and then NT + PIO were controlled by micropumps. Resting cell length, time to peak (TPK) shortening, time to half (THALF) relaxation and amplitude of shortening (expressed as a % of resting cell length) were measured in electrically stimulated (1 Hz) myocytes maintained at 35-36 °C before and after PIO. Myocytes with normal rod-shaped morphology and stable shortening during electrical stimulation were selected for experiments. Data were acquired and analyzed with Signal Averager software v 6.37 (Cambridge Electronic Design, Cambridge, UK).
Measurement of intracellular Ca 2+ transient
Myocytes were loaded with the fluorescent indicator fura-2 AM (F-1221, Molecular Probes, Eugene, OR, USA) according to previously described techniques (Salem et al. 2013) . In brief, 6.25 µl of a 1.0 mM stock solution of fura-2 AM (dissolved in dimethylsulphoxide) was added to 2.5 ml of cells to give a final fura-2 concentration of 2.5 µM. Myocytes were shaken gently for 10 min at room temperature (24 °C). After loading with fura-2 AM, myocytes were centrifuged, washed with NT to remove extracellular fura-2 and then left for 30 min to ensure complete hydrolysis of the intracellular ester. To measure intracellular Ca 2+ transients, myocytes were alternately illuminated by 340 and 380 nm light using a monochromator (Cairn Research, Faversham, UK) which changed the excitation light every 2 ms. The resulting fluorescence emitted at 510 nm was recorded by a photomultiplier tube and the ratio of the emitted fluorescence at the two excitation wavelengths (340/380 ratio) was calculated to provide an index of intracellular Ca 2+ concentration. Resting fura-2 ratio, 
Assessment of myofilament sensitivity to Ca
2+
In some cells shortening and fura-2 ratio were recorded simultaneously (Howarth et al. 2011) . Myofilament sensitivity to Ca 2+ was assessed from phaseplane diagrams of fura-2 ratio versus cell length by measuring the gradient of the fura-2 -cell length trajectory during late relaxation of the twitch contraction before and after PIO. The position of the trajectory reflects the relative myofilament response to Ca 2+ and hence, can be used as a measure of myofilament sensitivity to Ca 2+ (Spurgeon et al. 1992, Howarth and .
Measurement of sarcoplasmic reticulum Ca 2+ transport
Sarcoplasmic reticulum (SR) Ca 2+ was assessed using previously described techniques (Howarth et al. 1999 , Howarth et al. 2002 , Bassani et al. 1995 . After establishing steady state Ca 2+ transients in electrically stimulated (1 Hz) myocytes maintained at 35-36 °C and loaded with fura-2, stimulation was paused for a period of 5 s. Caffeine (20 mM) was then applied rapidly using a solution switching device (Levi et al. 1996 Electrode resistances ranged from 3 to 5 MΩ, and seal resistances were 1-5 GΩ. Series resistances were compensated to >75 % of the uncompensated value. Experiments were performed at 34-36 °C before and after PIO. The currentvoltage relationship was obtained by applying 300 ms test pulses in the range -60 mV to +70 mV in 10 mV steps from a holding potential of -50 mV. The steady-state inactivation of Ca 2+ current was measured as the relationship of amplitude of the peak current at a test pulse of 0 mV to amplitude of peak current at 1,000 ms long pre-pulses to various voltages between -60 and +30 mV. Normalized peak currents measured after these pre-pulses were plotted against the respective pre-pulse potential. Time course of recovery from inactivation was investigated using a two-pulse protocol. Two 100 ms depolarizing pulses to +10 mV were separated by inter-pulse intervals with variable duration. Peak Ca 2+ current amplitude measured by the second pulse was normalized to that measured by the first pulse and their ratio was plotted against the inter-pulse interval. Data were acquired and analyzed with pCLAMP software 8.2
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(Axon Instruments Inc, Union City, CA, USA).
Drug preparation PIO (E6910, Sigma-Aldrich) was dissolved in 100 % DMSO to produce 0.5, 5 and 50 mM stock solutions which were stored at -20 °C. Experimental PIO solutions were prepared by addition of stock solutions to NT with final DMSO concentration of 0.02 % in all test solutions.
Statistical analysis
Results are expressed as the mean ± SEM of 'n' observations. 'n' refers to number of animals or ventricular myocytes. Data were analyzed by the Independent samples t-test, Paired samples t-test or as appropriate using IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp, Armonk, NY, USA). Statistical significance was set at P<0.05.
Results
Experiments were performed in cardiac myocytes isolated from GK rats, aged 8-10 months, and age-matched controls. Body weight, heart weight and non-fasting blood glucose were measured immediately before experiments. The results are shown in Table 1 . Body weight and heart weight were significantly (P<0.01) higher in GK compared to control rats. Non-fasting blood glucose was significantly (P<0.01) elevated in GK compared to control rats. Heart weight to body weight ratio was not significantly (P>0.05) altered in GK compared to control rats. Figure 1 shows the effects of different concentrations of PIO (0.1-10 µM) on the amplitude of myocyte shortening. Amplitude of shortening was significantly (P<0.05) and progressively reduced in GK myocytes following treatment with 1 and 10 μM PIO and in control myocytes following treatment with 0.1, 1 and 10 µM PIO. 1 µM PIO was selected for further studies because it produced a response intermediate between 0.1 and 10 µM and is considered a concentration that is clinically relevant (Budde et al. 2003) . A typical recording of shortening in a GK myocyte superfused with NT or NT + 1 μM PIO is shown in Figure 2A . Resting cell length was not significantly (P>0.05) altered in GK myocytes compared to controls or by PIO (Fig. 2B) . TPK shortening was significantly (P<0.05) prolonged in GK and control myocytes and THALF relaxation of shortening was significantly (P<0.05) prolonged only in GK myocytes with 1 μM PIO (Figs 2C, D) . Amplitude of shortening was unaltered in GK myocytes compared to controls, PIO significantly (P<0.05) reduced amplitude of shortening in GK (80.2±2.7 %, n=24) and control (83.84±3.16 %, n=22) myocytes (Fig. 2E) . 
Effects of acute pioglitazone on ventricular myocyte shortening
Effects of acute pioglitazone on ventricular myocyte intracellular Ca 2+ transient
A typical recording of Ca 2+ transient in a GK myocyte superfused with NT or NT + 1 μM PIO is shown in Figure 3A . Resting fura-2 ratio was not significantly (P>0.05) altered in GK or control myocytes or by PIO (Fig. 3B) . TPK Ca 2+ transient was prolonged by PIO in GK and control myocytes (Fig. 3C) . THALF decay of the Ca 2+ transient was significantly (P<0.05) shortened in GK compared to control myocytes (Fig. 3D) . Amplitude of the Ca 2+ transient was significantly (P<0.05) reduced in GK and control myocytes by PIO (Fig. 3E ).
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Effects of pioglitazone on myofilament sensitivity to Ca
2+
In some experiments myocyte shortening and intracellular Ca 2+ transient were recorded simultaneously.
Typical records of myocyte shortening and fura-2 ratio in NT and a typical phase plane diagram of fura-2 ratio vs. cell length in NT are shown in Figure 4A and B, respectively. The gradient of the fura-2 cell length trajectory during late relaxation of the twitch contraction was not significantly (P>0.05) altered in GK compared to control myocytes or by PIO during the periods 500-800 ms (Fig. 4C) , 500-700 ms (Fig. 4D ) and 500-600 ms (Fig. 4E) . 
Effects of pioglitazone on sarcoplasmic reticulum Ca
2+ transport
The effects of PIO on SR Ca 2+ were assessed in fura-2 loaded myocytes from GK and control rat. A typical record of the experimental protocol in a control myocyte is shown in Figure 5A . Caffeine-induced Ca 2+ release from the SR was not significantly altered in GK compared to control myocytes or by PIO (Fig. 5B) . Recovery of the Ca 2+ transient following application of caffeine was not significantly (P>0.05) altered in GK compared to control myocytes or by PIO (Fig. 5C) . 
Effects of pioglitazone on L-type Ca 2+ current
The electrophysiological protocols (upper panel) that were used and typical current records of Ca 2+ current in a control myocyte (lower panel) during activation, inactivation and restitution experiments are shown in Figure 6A , B and C, respectively. Over a range of test potentials the amplitude of L-type Ca 2+ current was not significantly (P>0.05) reduced in GK compared to control myocytes or by PIO (Fig. 6D) . At a test potential of 0 mV the amplitude of L-type Ca 2+ current was largest in control myocytes (7.4±1.3 pA/pF, n=11), then control myocytes with PIO (6.1±1.4 pA/pF, n=9), then GK myocytes (5.8±0.9 pA/pF, n=10) and smallest in GK myocyte with PIO (5.0±0.7 pA/pF, n=9) however, these differences were not significant (P>0.05) (Fig. 6E) . Inactivation of L-type Ca 2+ current, was not significantly (P>0.05) altered in GK compared to control myocytes or by PIO (Fig. 6F) . Similarly, the time course of recovery from inactivation was not significantly (P>0.05) altered in GK compared to control myocytes or by PIO (Fig. 6G ).
Discussion
In recent years, much of the research has focused on the potential effects of PIO on cardiovascular function. At the cellular level the actions of PIO in diabetic heart are poorly understood. The effects of PIO on ventricular myocyte shortening and Ca 2+ transport have been investigated in this study. The major findings were:
(1) PIO in the range 0.1-10 µM reduced the amplitude of shortening to similar extents in GK and control myocytes, Experiments were performed in GK rats, 8-10 months of age, and age-matched controls. Diabetes status was confirmed by elevated blood glucose, a finding that is consistent with previous studies . It has been reported that blood glucose is elevated from as young as 1 month in GK rats (Portha et al. 1991) . Body weight was higher in GK rats compared to controls. PIO belongs to the thiazolidinedione group of oral antidiabetic agents, which act as full agonists of PPARγ which is associated with glucose homeostasis (Willson et al. 1996 , Zhang et al. 2007 , Picard and Auwerx 2002 , Gurnell et al. 2003 . Many experimental and clinical studies have demonstrated the favorable effects of PIO on the modulation of cardiovascular risk factors related to T2DM (Lincoff et al. 2007 , Dormandy et al. 2005 , Van der Meer et al. 2009 , Kim et al. 2003 , Rodriguez et Vol. 67 al. 2006 . Furthermore, previous studies have shown that the effects of PIO on the cardiovascular system are initiated at the pre-diabetes stage in type 2 diabetic rat (Tsuji et al. 2001) . In this study 1 µM PIO significantly reduced the amplitude and prolonged the TPK shortening in GK and control myocytes to similar extents. Resting cell length was not altered in GK compared to control myocytes or by PIO. In a previous study PIO treatment reduced cardiac cell length in myocytes from transgenic rats over expressing renin compared to non-transgenic littermates (Hinrichs et al. 2011 In conclusion, the negative inotropic effects of PIO in GK and control myocytes are similar and may partly be attributed to a reduction in Ca 2+ transient however, the mechanisms remain to be resolved.
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